Tcheng, James E <br/><br/>
Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.  [electronic resource] 

 -  Circulation  Sep 2003 
 - 1316-23 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1524-4539 
<br/><br/><label>Standard No.: </label>10.1161/01.CIR.0000087601.45803.86  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abciximab<br/>Adult<br/>Aged<br/>Angioplasty, Balloon, Coronary<br/>Antibodies, Monoclonal--adverse effects<br/>Combined Modality Therapy<br/>Coronary Angiography<br/>Endpoint Determination<br/>Female<br/>Humans<br/>Immunoglobulin Fab Fragments--adverse effects<br/>Male<br/>Middle Aged<br/>Myocardial Infarction--diagnosis<br/>Platelet Aggregation Inhibitors--adverse effects<br/>Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors<br/>Stents<br/>Treatment Outcome